CSIRO looks to get into medicinal cannabis to take advantage of US$44bn marketPosted by On


Cannabis cough lollies and a variety of products harnessing the medicinal properties of marijuana could soon be produced by Australia’s national science agency as it looks to position the country at the forefront of what could be a US$44 billion global industry by 2024.

CSIRO is currently the only independent research institute in Australia able to develop drug manufacturing protocols in the medicinal cannabis space, and the agency has been granted a new licence to partner with local manufacturers to produce therapeutics.

CSIRO scientist Professor Peter Duggan told The West Live the new licence would bridge the gap between growing the cannabis plants and turning the plants into medicines.

“There’s already more than 20 (medicinal cannabis companies) on the stock exchange, and a number of private companies as well, so there is a huge amount of interest on the Australian scene,” Professor Duggan said.

A worker wearing protective gear trims a plant at the Pideka SAS medical cannabis cultivation facility in Tocancipa, Colombia.
Camera IconA worker wearing protective gear trims a plant at the Pideka SAS medical cannabis cultivation facility in Tocancipa, Colombia. Credit: Ivan Valencia/Bloomberg

“But one of the issues is a lot of these companies have been focused on growing the plants, getting the right genetics, learning how to dry them, and there hasn’t been a lot of work on the next stage, which is producing actual medicines.”

Professor Duggan said smoking a joint wasn’t an acceptable way to absorb medicinal cannabis in Australia, so the simplest vehicle for the delivery of such medicine…

Original Author Link click here to read complete story..

Cannabis cough lollies and a variety of products harnessing the medicinal properties of marijuana could soon be produced by Australia’s national science agency as it looks to position the country at the forefront of what could be a US$44 billion global industry by 2024.

CSIRO is currently the only independent research institute in Australia able to develop drug manufacturing protocols in the medicinal cannabis space, and the agency has been granted a new licence to partner with local manufacturers to produce therapeutics.

CSIRO scientist Professor Peter Duggan told The West Live the new licence would bridge the gap between growing the cannabis plants and turning the plants into medicines.

“There’s already more than 20 (medicinal cannabis companies) on the stock exchange, and a number of private companies as well, so there is a huge amount of interest on the Australian scene,” Professor Duggan said.

A worker wearing protective gear trims a plant at the Pideka SAS medical cannabis cultivation facility in Tocancipa, Colombia.
Camera IconA worker wearing protective gear trims a plant at the Pideka SAS medical cannabis cultivation facility in Tocancipa, Colombia. Credit: Ivan Valencia/Bloomberg

“But one of the issues is a lot of these companies have been focused on growing the plants, getting the right genetics, learning how to dry them, and there hasn’t been a lot of work on the next stage, which is producing actual medicines.”

Professor Duggan said smoking a joint wasn’t an acceptable way to absorb medicinal cannabis in Australia, so the simplest vehicle for the delivery of such medicine…



Source link

News

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.